What is Aspect Biosystems?
Headquartered at the intersection of advanced manufacturing and life sciences, Aspect Biosystems is a biotechnology firm dedicated to the development of 3D bioprinted human tissues. The company's core innovation, the Lab-on-a-Printer platform, enables the creation of complex, functional biological structures that mimic human physiology. By bridging the gap between traditional in vitro models and clinical outcomes, Aspect provides pharmaceutical and biotechnology partners with high-fidelity tools to accelerate the development of novel therapeutics. Their market position is defined by a dual-track strategy: advancing internal drug discovery programs while simultaneously establishing high-value partnerships to integrate their bioprinting technology into global research workflows.
How much funding has Aspect Biosystems raised?
Aspect Biosystems has raised a total of $215M across 4 funding rounds:
Other Financing Round
$1M
Series A
$20M
Series B
$115M
Unspecified
$79M
Other Financing Round (2018): $1M with participation from Genome British Columbia
Series A (2020): $20M led by Rhino Ventures, Pangaea Ventures, Pallasite Ventures, and Radical Ventures
Series B (2025): $115M supported by Pallasite Ventures, Novo Nordisk, Radical Ventures, Rhino Ventures, JDRF T1D Fund, Dimension Data, InBC Investment, and Pangaea Ventures
Unspecified (2026): $79M featuring Government of Canada
Key Investors in Aspect Biosystems
Pangaea Ventures
A leading venture capital firm specializing in hard tech, focusing on investments in start-ups that utilize advancements in materials, chemistry, and biology to tackle significant global challenges.
Novo Nordisk
A global pharmaceutical leader focused on developing innovative medicines and drug delivery systems for the treatment of serious chronic diseases, including diabetes and obesity.
Pallasite Ventures
An agile venture capital firm based in Vancouver that provides early-stage financing and strategic support for high-growth companies across the technology and life sciences sectors.
What's next for Aspect Biosystems?
With the recent infusion of capital, Aspect Biosystems is well-positioned to expand its operational footprint and deepen its strategic collaborations within the pharmaceutical industry. The company is expected to prioritize the scaling of its bioprinting infrastructure to meet the growing demand for human-relevant tissue models in drug development. Furthermore, the strategic backing from both institutional investors and government entities suggests a long-term commitment to establishing the firm as a cornerstone of the regenerative medicine ecosystem. Future milestones will likely focus on the commercial validation of their proprietary tissues and the potential expansion of their therapeutic pipeline, leveraging the platform's unique ability to address complex biological challenges.
See full Aspect Biosystems company page
